Pfizer management commentary cites non-COVID product growth as driver of Q3 2026 performance
PFE•PFE•PFE•PFE•Pfizer raised its full-year 2026 revenue guidance to $62 billion-$64 billion and adjusted diluted EPS guidance to $2.95-$3.05. Third-quarter revenue was $16.6 billion, while adjusted diluted EPS was $0.87, including a $0.10 Innovent transaction charge.
Pfizer raised its full-year 2026 revenue guidance to $62 billion-$64 billion, citing non-COVID product growth and disciplined execution. Adjusted diluted EPS guidance increased to $2.95-$3.05, absorbing a $0.10-per-share charge related to the Innovent transaction.
Third-quarter revenue reached $16.6 billion, exceeding management expectations. Non-COVID products grew 7% operationally, offset by lower COVID-19 product revenue; adjusted diluted EPS was $0.87. Launched and acquired products generated $3.8 billion in revenue, up 32% operationally, primarily driven by Padcev, Nurtec and Lorbrena.
